Share Name Share Symbol Market Type Share ISIN Share Description
Novacyt S.a. LSE:NCYT London Ordinary Share FR0010397232 EUR1/15TH (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  64.00 5.68% 1,190.00 641,714 16:35:02
Bid Price Offer Price High Price Low Price Open Price
1,178.00 1,182.00 1,206.00 1,130.00 1,130.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.08 -3.91 -14.00 840
Last Trade Time Trade Type Trade Size Trade Price Currency
16:40:00 O 2,380 1,174.642 GBX

Novacyt (NCYT) Latest News

More Novacyt News
Novacyt Investors    Novacyt Takeover Rumours

Novacyt (NCYT) Discussions and Chat

Novacyt Forums and Chat

Date Time Title Posts
22/1/202113:19CV and The Deep State124
08/1/202110:31COVID-19..downgraded no longer high consequence infectious disease37
07/12/202007:54coronavirusTransmission facts vs fiction442
19/11/202019:39black cloud3

Add a New Thread

Novacyt (NCYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-25 17:20:281,174.642,38027,956.48O
2021-01-25 17:18:001,177.752,21426,075.39O
2021-01-25 17:15:011,173.0017,051200,008.23O
2021-01-25 17:15:011,192.9618,263217,870.28O
2021-01-25 17:15:011,192.9634,049406,190.95O
View all Novacyt trades in real-time

Novacyt (NCYT) Top Chat Posts

Novacyt Daily Update: Novacyt S.a. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NCYT. The last closing price for Novacyt was 1,126p.
Novacyt S.a. has a 4 week average price of 796p and a 12 week average price of 550p.
The 1 year high share price is 1,260p while the 1 year low share price is currently 14.50p.
There are currently 70,626,248 shares in issue and the average daily traded volume is 577,388 shares. The market capitalisation of Novacyt S.a. is £840,452,351.20.
rcturner2: The share price is going to move around until the actual FY numbers are known and then the price will move to a level that reflects those numbers, for good or bad.
bobdown2: I used to buy when the share price was on the offer and then the share price went down. The dropping of the bid today followed by a small sale and then a dropping of the offer explains the above. It's how the mms consolidate. I will watch a few more quick rising shares and see if the mms are consistent.
bobdown2: Uk2day. I believe the mms have the ability to short 10% which if the share price rises dramatically what is do stop them from driving the price down. The recent news suggests a much, much higher share price. Whilst I do not normally give predictions.! I think it could quite easily double from here. Mms should not have the advantage to change the market to suite themselves. The word is equivalence.
bobdown2: This promate news just before the update is very reassuring. As the product gains traction it will be the share price driver after the update and encourage long term holding instead of short term. Anyone treating this share as a normal one and sells will lose the hedge against the virus. After the recent rise you could not blame anyone for profit taking. But these are not normal times.
routy: From a Dutch Financial Blog - well worth a read...A hit. That was our blog on February 1, 2020. Almost a year ago, we tipped Novacyt stock for its enormous price potential, after the company took the lead in developing a test for the corona virus. The share price rose that day from EUR 0.25 to EUR 0.45, or a gain of 81%. Many thought we were crazy when we set a target price of EUR 7 for this stock. Once the stock was discovered last year, it exploded to EUR 14. After a pause in the upward trend around EUR 8, the share has now returned to EUR 12. In our opinion, this is the start of a second price explosion. The company is in good shape and with the new corona mutations, another turnover / profit explosion can be expected. Our target price is EUR 45 for the coming year.The small company Novacyt has suddenly become a big boy due to the corona pandemic. Where the turnover for 2019 was only EUR 13 million, resulting in a small loss, the turnover for 2020 will be at least EUR 150 million. And we think that is still on the meager side. Sales for the first half of last year amounted to EUR 72 million with EPS of 0.61. In the second half of the year, the number of tests only increased further. That is why we believe that the expectations that the CEO gave last year of a turnover of at least EUR 150 million will be exceeded. We are thinking of an EPS of EUR 2 over last year.The corona virus mutates. It seems like this comes as a surprise to the world, while viruses are generally known to always mutate. The British corona mutant is now in the news. Then there was a South African mutant. Now it turns out there is also a Brazilian and German mutant. This just goes on and on. And the tests have to be adjusted accordingly. Novacyt is developing new tests for the mutants. The world seems to assume that corona will soon be over, now that there are several vaccines and people have already been vaccinated and are being vaccinated on a large scale. Multiple studies show that corona will likely rule our lives for years to come. Although that is terrible for everyone, there are companies that profit from this. Novacyt is at the forefront of taking advantage of this. This year, but also in the coming years, testing will be indispensable. That is not only testing in case of complaints, but also when traveling by airplanes, trains, buses, etc., etc. It will also not surprise us if you will be tested in the coming years when you visit a museum, a concert, a cinema or a soccer game. The number of tests we now see worldwide will only increase.Based on further revenue growth and thus profit growth, we think there is a lot of potential in Novacyt's share price. If Novacyt presents a EPS of EUR 2 for 2020, at a price of EUR 12, that would mean a price earnings ratio of 6. In 2021 we expect an EPS of EUR 3. We value a stock like Novacyt, based on the risk of the product. and period-related revenue / profit explosions, at 15. That would mean a target price of EUR 45 for this year.Price: 1,088.00We know all too well that predicting numbers for a company like Novacyt is extremely difficult. Many will agree with us about our expectations, but some will not at all. That is why we want to make it clear that this is absolutely not investment advice to you. In any case, we will continue to hold on to our shares! In a year's time we will see whether our expectations have actually come true.
the patient investor: This is fantastic news! Do you know who James is!!?? When a director buys shares is good news but when the CFO buys 90k £ worth of shares is VERY good news!! 13/11/2020 6:05pm UK Regulatory (RNS & others) TIDMNCYT RNS Number : 3414F Novacyt S.A. 13 November 2020 Novacyt S.A. ("Novacyt" or the "Company") Director/PDMR Shareholding Paris, France and Camberley, UK - 13 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 13 November 2020, James McCarthy (PDMR), a corporate consultant, acquired 10,000 ordinary shares of EUR1/15 each in the Company at an average price of GBP8.953 per share. The resultant beneficial shareholding of Mr McCarthy is 10,000 ordinary shares representing 0.01% of the Company's issued share capital. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
the patient investor: uva sonicboomboy Today 09:18 Posts: 1,278 Price: 848.00 No Opinion I think today's share price action reflects the 3 things: 1. VACCINES - any negative fall out is now priced in with still many questions over efficacy , transission etc 2. The COVID situation - remains out of control and testing will be required for a long time WORLDWIDE. 3. The RESULTS are likely to be worse case inline with BROKER forecasts therefore we are undervalued by 50% as we stand.
turvart: Cheers Bunz. NCYT is in a weird area because no one really knows what full year profits are going to be? I guess with all my research and watching what other people state that net profit should be around 280-400 mln area. Now lets take the smaller figure 280 Mln and use a PE of 10 that is more than sensible to use, that puts NCYT on a m/cap of 2.8 BLN that is £39.43 per share. Loads of derampers will scream "no way! it was 10p in January" well yeah OK but Covid 19 was not about in the UK then and until NCYT announced they compiled a covid test then not many heard of NCYT (I certainly didn't hear of NCYT before Covid). Any way things have changed since January and with NCYT. The company was actually making a loss each year and had a fair amount of debt. The debt is now paid in full and covid has turned the company into a gold mine. GM is looking at ways to diversify and grow Novacyt into a world leading In-vitro diagnostics company and achieve acquisitions to accomplish this goal for future earnings. I still honestly believe from this current share price level that NCYT can and WILL 10 bag. This may seem a crazy comment at todays share price level, but IMO the current PE ratio is at a crazy low level because the market needs to see some final results, the PE ratio at current is probably on 2 of which is just crazy IMO.
the patient investor: Great posts this morning, the FT article is almost an indirect "strong buy" recommendation for ncyt. It is so obvious the demand for our PCR tests will go through the roof and the expected results by the end of January will be amazing. I actually expect a mind-blowing trading update soon and let's not forget the very imminent launch of our two own rapid tests as per the recent RNS of 16 November. Ah, another point is, the FT article refers, obviously, only to the UK demand for the PCR tests, so I just cannot even imagine the figures for the world market and in particular the U.S. market which is our main one. Astonishing times ahead. Buying NCYT shares at this price is like printing money. hTtps:// QUOTE Development of a LAMP COVID-19 test L oop-mediated isothermal amplification ( LAMP ) technology is a single-tube technique for the amplification of DNA and RNA and is considered a low-cost alternative to detect certain diseases , including COVID-19. I sothermal amplification is carried out at a constant temperature without the need for a thermal cycler, contrast ing to PCR amplification, which is carried out with a series of alternating temperature steps or cycles in a thermal cycler . Novacyt is currently developing a LAMP test for COVID-19, including evaluating the trade-off between cycle time and test performance . The Company expects to launch the product during Q1 2021 with an expected cycle time of 20 minutes or lower. Novacyt's LAMP offering is designed to be compatible with its q16 and q32 instruments . The Company is also in active discussions with several potential partners who are seeking support to develop, manufacture and supply LAMP tests for their instrument platforms. Development of an antibody lateral flow test for COVID-19 On 29 September 2020, Novacyt announced the launch of its IgG specific antibody test for use in central laboratory testing. The Company is also working on developing an IgG antibody lateral flow test (LFT) for use as a rapid antibody test for professional use. An LFT is an easy-to-use diagnostic device used to confirm the presence or absence of a pathogen or biomarker. The product is expected to launch during Q1 2021 and is expected to take approximately 20 minutes or less to give a result. UNQUOTE Easily 15 quid soon.
Novacyt share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210126 03:50:28